Sensus Healthcare (NASDAQ:SRTS) Cut to “Sell” at Wall Street Zen

Sensus Healthcare (NASDAQ:SRTS) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Thursday.

Several other research firms also recently weighed in on SRTS. Maxim Group reduced their price objective on shares of Sensus Healthcare from $14.00 to $10.00 and set a “buy” rating for the company in a report on Monday, May 19th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Sensus Healthcare in a report on Friday, April 4th. Finally, Lake Street Capital reduced their price objective on shares of Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

Sensus Healthcare Stock Performance

Shares of SRTS opened at $4.69 on Thursday. Sensus Healthcare has a 1 year low of $4.01 and a 1 year high of $9.33. The company has a market cap of $77.13 million, a price-to-earnings ratio of 11.73 and a beta of 1.30. The firm has a fifty day moving average of $4.61 and a 200-day moving average of $6.06.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.20). The company had revenue of $8.34 million during the quarter, compared to analyst estimates of $7.23 million. Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. Analysts predict that Sensus Healthcare will post 0.32 EPS for the current year.

Institutional Investors Weigh In On Sensus Healthcare

Several hedge funds and other institutional investors have recently bought and sold shares of SRTS. Acadian Asset Management LLC raised its position in Sensus Healthcare by 35.3% in the first quarter. Acadian Asset Management LLC now owns 470,713 shares of the company’s stock worth $2,225,000 after acquiring an additional 122,746 shares in the last quarter. Pacific Ridge Capital Partners LLC bought a new stake in Sensus Healthcare in the first quarter worth about $542,000. Dimensional Fund Advisors LP raised its position in Sensus Healthcare by 30.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company’s stock worth $2,620,000 after acquiring an additional 88,953 shares in the last quarter. Meros Investment Management LP bought a new stake in Sensus Healthcare in the first quarter worth about $419,000. Finally, Arrowstreet Capital Limited Partnership raised its position in Sensus Healthcare by 81.2% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company’s stock worth $1,039,000 after acquiring an additional 67,269 shares in the last quarter. 25.30% of the stock is currently owned by institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.